Five blockbuster candidates less than two years away, says Novartis

23 May 2019

At an investor event at its US R&D base, Swiss pharma giant Novartis (NOVN: VX) has reiterated its strategy to “become a leading medicines company powered by advanced therapy platforms and data science.”

Chief executive Vas Narasimhan said the firm was “on track to deliver sustained accretive growth,” adding that its pipeline was “industry-leading.”

Executives highlighted what they saw as the continued strength of interleukin (IL)-17 blocker Cosentyx (secukinumab) and heart med Entresto (sacubitril/valsartan), including new data from the PIONEER study which will support hospital initiation of the latter product.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK